Wockhardt Expects To Resolve Five-Year-Old U.S. Ban On Facility Soon
Wockhardt Ltd. said it's in final stages to resolve the U.S. drug regulator's import alert for one of the three plants that can't export drugs to the American market because of lack of good manufacturing standards.
The company is in the last lap of remedial efforts for Waluj, Maharashtra facility, Murtaza Khorakiwala, managing director at Wockhardt, told BloombergQuint in an interview. The corrective steps that include changing processes and employees were almost complete, he said, and the company will be able to invite the U.S. Food and Drug Administration for a re-inspection in a couple of months.
The plant was barred from exporting drugs to U.S. in 2013. The same year, the regulator issued an import alert to its another facility in Chikalthana, Maharashtra, and followed that up with similar action against Wockhardt's third facility in Ankleshwar, Gujarat in 2016.
The contribution of the U.S. market to Wockhard's sales has fallen from about 50 percent to nearly 17 percent now since it ran into regulatory troubles, according to Bloomberg data. As a result, shares of the drugmaker have tumbled nearly 75 percent from their all-time peak. It has about 70 drug filings pending with the U.S. FDA.
Khorakiwala said the company is looking at resolving the issues in phases, starting with Waluj. The remedial steps for Chikalthana and Ankleshwar plants will start only after Waluj gets clearance, he said.
Other key highlights from the interview
On Pharmaceutical Industry
- The Indian pharma industry has moved beyond the impact of GST and demonetisation.
- The global market is becoming more competitive and price conscious.
On New Chemical Entity Drugs
- The company is betting on the new chemical entity pipeline.
- Drugs under clinical trials which will be launched soon.
- One drug has completed phase 3 trials in India which will be launched next year.
- Two other drugs will start global clinical trials soon.
On U.S. FDA Resolution For Plants
- Have invested in remedial aspects of plants over past the few years.
- In discussion with the regulator to answer their queries on plants.
On Selling Business
- Cannot comment on any possible mergers and acquisitions.
- Not looking to sell India business—it will the growth engine of the company.
Watch the interview here
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.